PMC:7102591 / 21223-23181
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
633 | 5-35 | Chemical | denotes | Chloroquine/hydroxychloroquine | |
640 | 460-476 | Species | denotes | SARS coronavirus | Tax:694009 |
641 | 36-47 | Chemical | denotes | Chloroquine | MESH:D002738 |
642 | 52-70 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
643 | 257-268 | Chemical | denotes | chloroquine | MESH:D002738 |
644 | 191-222 | Disease | denotes | immuno-rheumatological diseases | MESH:D000163 |
645 | 233-235 | Disease | denotes | RA | MESH:D001172 |
657 | 835-840 | Gene | denotes | ACE 2 | Gene:59272 |
658 | 1338-1346 | Species | denotes | patients | Tax:9606 |
659 | 640-651 | Chemical | denotes | chloroquine | MESH:D002738 |
660 | 1059-1070 | Chemical | denotes | chloroquine | MESH:D002738 |
661 | 1370-1381 | Chemical | denotes | chloroquine | MESH:D002738 |
662 | 1623-1641 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
663 | 1695-1706 | Chemical | denotes | chloroquine | MESH:D002738 |
664 | 1021-1039 | Disease | denotes | SARS CoV infection | MESH:C000657245 |
665 | 1210-1218 | Disease | denotes | COVID-19 | MESH:C000657245 |
666 | 1486-1495 | Disease | denotes | pneumonia | MESH:D011014 |
667 | 1932-1952 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T77 | 676-685 | Body_part | denotes | endosomal | http://purl.org/sig/ont/fma/fma67180 |
T78 | 708-712 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T79 | 1432-1436 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T21 | 1432-1436 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid_AGAC
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
p51644s32 | 787-809 | MPA | denotes | terminal glycosylation |
p51645s8 | 915-932 | MPA | denotes | -receptor binding |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T245 | 233-235 | Disease | denotes | RA | http://purl.obolibrary.org/obo/MONDO_0005272|http://purl.obolibrary.org/obo/MONDO_0008383 |
T247 | 460-464 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T248 | 1021-1025 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T249 | 1030-1039 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T250 | 1210-1218 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T251 | 1486-1495 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
T252 | 1932-1940 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T253 | 1943-1952 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T144 | 301-304 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T145 | 441-448 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T146 | 702-707 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T147 | 708-712 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T148 | 755-763 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T149 | 910-915 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T150 | 947-948 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T151 | 1044-1045 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T152 | 1071-1074 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T153 | 1182-1188 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T154 | 1432-1436 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T155 | 1432-1436 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T156 | 1507-1508 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T157 | 1509-1514 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T158 | 1824-1825 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T169 | 5-16 | Chemical | denotes | Chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T170 | 17-35 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T171 | 36-47 | Chemical | denotes | Chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T172 | 52-70 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T173 | 101-106 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T174 | 233-235 | Chemical | denotes | RA | http://purl.obolibrary.org/obo/CHEBI_73810 |
T175 | 257-268 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T176 | 375-379 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T177 | 640-651 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T178 | 973-977 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T179 | 1059-1070 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T180 | 1275-1280 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T181 | 1370-1381 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T182 | 1623-1641 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T183 | 1695-1706 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T40 | 410-416 | http://purl.obolibrary.org/obo/GO_0040007 | denotes | growth |
T41 | 708-719 | http://purl.obolibrary.org/obo/GO_0140253 | denotes | cell fusion |
T42 | 708-719 | http://purl.obolibrary.org/obo/GO_0045026 | denotes | cell fusion |
T43 | 708-719 | http://purl.obolibrary.org/obo/GO_0000768 | denotes | cell fusion |
T44 | 708-719 | http://purl.obolibrary.org/obo/GO_0000747 | denotes | cell fusion |
T45 | 746-763 | http://purl.obolibrary.org/obo/GO_0038024 | denotes | receptor activity |
T46 | 787-809 | http://purl.obolibrary.org/obo/GO_0033578 | denotes | terminal glycosylation |
T47 | 796-809 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T119 | 0-35 | Sentence | denotes | 5.1 Chloroquine/hydroxychloroquine |
T120 | 36-241 | Sentence | denotes | Chloroquine and hydroxychloroquine are widely used anti-malarial drugs with well-known immunomodulatory properties that have extended their use to several immuno-rheumatological diseases including RA [83]. |
T121 | 242-342 | Sentence | denotes | The ability of chloroquine to produce an anti-viral effect has been known since the late 1960s [84]. |
T122 | 343-599 | Sentence | denotes | Several mechanisms by which the drug is able to interfere with the growth and spread of different viruses (including SARS coronavirus) have been demonstrated in in vitro studies [85], even though the subsequent in vivo experience was controversial [86,87]. |
T123 | 600-860 | Sentence | denotes | At clinically admissible concentrations chloroquine is able to increase the endosomal pH required for virus/cell fusion, to inhibit the toll-like receptor activity, and to interfere with terminal glycosylation of the cellular receptor ACE 2 [[88], [89], [90]]. |
T124 | 861-1040 | Sentence | denotes | All these functions may negatively influence the virus-receptor binding, resulting in a potential effect of the drug on both entry and post-entry stages of the SARS CoV infection. |
T125 | 1041-1302 | Sentence | denotes | As a consequence, chloroquine has recently been included in at least 10 randomized controlled trials currently ongoing in China, where it is tested for the treatment of COVID-19 under various combination protocols with the anti-viral drugs mentioned above [91]. |
T126 | 1303-1607 | Sentence | denotes | Interim results from more than 100 patients have demonstrated that chloroquine is superior to the control treatment in improving lung imaging findings, inhibiting the exacerbation of pneumonia, promoting a virus negative conversion, and shortening the disease course at different levels of severity [92]. |
T127 | 1608-1767 | Sentence | denotes | More recently, hydroxychloroquine was demonstrated to be more 3-times more potent than chloroquine in an in vitro study based on pharmacokinetic models (PBPK). |
T128 | 1768-1958 | Sentence | denotes | An oral loading dose of 400 mg twice daily, followed by a maintenance dose of 200 mg given twice daily for 4 days seems to be the best option for the management of SARS-CoV-2 infection [93]. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T72 | 233-235 | Phenotype | denotes | RA | http://purl.obolibrary.org/obo/HP_0001370 |
T73 | 1486-1495 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32205186-32034323-4826913 | 237-239 | 32034323 | denotes | 83 |
32205186-4306296-4826914 | 338-340 | 4306296 | denotes | 84 |
32205186-21550310-4826915 | 592-594 | 21550310 | denotes | 86 |
32205186-16115318-4826916 | 843-845 | 16115318 | denotes | 88 |
32205186-16439323-4826917 | 855-857 | 16439323 | denotes | 90 |